
Immunization and Vaccine Payment Policy

Policy Statement

Immunizations and vaccinations for treatment of disease or prevention of infectious disease are covered. Neighborhood covers a set of immunizations and vaccines inclusive of the RI Department of Health's State Supplied Vaccine Schedule for children and adults. In addition to the State's Schedule, Neighborhood's Clinical Management Committee approves coverage of additional immunizations and vaccines that align with the benefit coverage dictated by its contract with the Department of Human Services.

Scope

This policy applies to:

- Medicaid
- INTEGRITY
- Commercial

Prerequisites

All services must be medically necessary to qualify for reimbursement. Neighborhood may use the following criteria to determine medical necessity:

- National Coverage Determination (NCD)
- Local Coverage Determination (LCD)
- Industry accepted criteria such as Interqual
- Rhode Island Executive Office of Health and Human Services (EOHHS) recommendations
- Clinical Medical Policies (CMP)

It is the provider's responsibility to verify eligibility, coverage and authorization criteria prior to rendering services.

For more information, please refer to:

- Neighborhood's plan specific [Prior Authorization Reference page](#).
- Neighborhood's [Clinical Medical Policies](#).

Please contact Provider Services at 1-800-963-1001 for questions related to this policy.



Reimbursement Requirements

Medicaid

Coverage Includes:

State supplied vaccines are provided by the Department of Health (DOH) at no cost to providers and practitioners; therefore, there is no reimbursement for the actual state supplied vaccines; although administration is covered.

Administration charges for all Centers for Disease Control (CDC) approved flu vaccines are covered regardless of whether the vaccine is state supplied or not. This only applies to the administration of these vaccines. Neighborhood will not reimburse providers for the vaccine charge.

Please refer to the RI DOH and CDC websites for a list of all current state supplied and CDC approved vaccines.

Immunizations and vaccines and/or their administrations are covered when administered by **Any** Provider. Please note, a provider may be located at a physician’s office, a hospital outpatient department, or a community health center.

The below table represents vaccines that may be covered and reimbursed by Neighborhood for ages outside of the RI DOH schedule.

Inclusion of a code in this list does not guarantee it will be reimbursed.

Procedure/Description	
90620	MENINGOCOCCAL (Serogroup B) 2 DOSE, IM
90621	MENINGOCOCCAL (Serogroup B) 3 DOSE, IM
90636	HEP A/HEP B VACCINE ADULT IM
90681	ROTAVIRUS , LIVE, 2 DOSE ORAL
90710	MMRV, LIVE, SUBCU
90713	POLIOVIRUS, INACTIVE, SUBCU OR IM
90733	MENINGOCOCCAL POLYSACCHARIDE, SEROGROUPS A,C,Y,W-135, QUAD, SUBCU
90736	ZOSTER (SHINGLES) LIVE, SUBCU
90740	HEPB VACC, ILL PAT 3 DOSE IM
90750	ZOSTER (shingles) VACC, IM
90675	RABIES VACCINE, IM
90676	RABIES VACCINE, ID

Coverage Limitations:

- Shingles Vaccines is limited to two (2) per lifetime
- HPV is limited to three (3) per lifetime
- Up to fifteen (15) administrations are reimbursable per day



- EFP Members are covered for state-supplied vaccines and immunizations and the corresponding administrations as part of their limited benefit package. All other vaccines/administration charges are non-covered.

Exclusions:

- Vaccines and immunizations for travel are not covered.

INTEGRITY

Coverage Includes:

State supplied vaccines are provided by the Department of Health (DOH) at no cost to providers and practitioners; therefore, there is no reimbursement for the actual state supplied vaccines; although administration is covered.

Administration charges for all Centers for Disease Control (CDC) approved flu vaccines are covered regardless of whether the vaccine is state supplied or not. This only applies to the administration of these vaccines. Neighborhood will not reimburse providers for the vaccine charge.

Please refer to the RI DOH and CDC websites for a list of all current state supplied and CDC approved vaccines.

Immunizations and vaccines and/or their administrations are covered when administered by **Any** Provider. Please note, a provider may be located at a physician’s office, a hospital outpatient department, or a community health center.

The below table represents vaccines that may be covered and reimbursed by Neighborhood for ages outside of the RI DOH schedule.

Inclusion of a code in this list does not guarantee it will be reimbursed.

Procedure/Description	
90620	MENINGOCOCCAL (Serogroup B) 2 DOSE, IM
90621	MENINGOCOCCAL (Serogroup B) 3 DOSE, IM
90636	HEP A/HEP B VACCINE ADULT IM
90656	FLU VACCINE, TRI, PRSV FREE, 4 YEARS & >, IM
90662	FLU VACC, PRSV FREE INC ANTIG, IM
90675	RABIES VACCINE, IM
90676	RABIES VACCINE, ID
90689	FLU VACCINE, QUAD IIV4, IM
90670	PNEUMOCOCCAL VACC, PCV13, IM
90732	PNEUMOCOCCAL POLYSACCHARIDE, 23 VALENT, ILL PAT, > 2 YEARS, SUBCU, IM
90733	MENINGOCOCCAL POLYSACCHARIDE, SUBCU

90736	ZOSTER VACC; SC
90740	HEP B, ILL PAT, 3 DOSE, IM
90750	ZOSTER (shingles) VACC, IM
Q2035	FLU VACCINE, SPLIT, 3 & >, IM (AFLURIA)

Coverage Limitations:

- Shingles Vaccines is limited to two (2) per lifetime.
- HPV is limited to three (3) per lifetime.
- Up to fifteen (15) administrations are reimbursable per day

Exclusions:

- Vaccines and immunizations for travel are not covered.

Commercial

Coverage Includes:

State-supplied vaccines are provided by the Department of Health (DOH) at no cost to providers and practitioners; therefore, there is no reimbursement for the actual state supplied vaccines; although administration is covered.

Administration charges for all Centers for Disease Control (CDC) approved flu vaccines are covered regardless of whether the vaccine is state supplied or not. This only applies to the administration of these vaccines. Neighborhood will not reimburse providers for the vaccine charge

Please refer to the RI DOH and CDC websites for a list of all current state supplied and CDC approved vaccines.

Immunizations and vaccines and/or their administrations are covered when administered by **Any** Provider. Please note, a provider may be located at a physician's office, a hospital outpatient department, or a community health center.

The below table represents vaccines that may be covered and reimbursed by Neighborhood for ages outside of the RI DOH schedule.

Inclusion of a code in this list does not guarantee it will be reimbursed.

Procedure/Description	
90620	MENINGOCOCCAL (Serogroup B) 2 DOSE, IM
90621	MENINGOCOCCAL (Serogroup B) 3 DOSE, IM
90636	HEP A/HEP B VACCINE ADULT IM
90681	ROTAVIRUS , LIVE, 2 DOSE ORAL

90710	MMRV, LIVE, SUBCU
90713	POLIOVIRUS, INACTIVE, SUBCU OR IM
90733	MENINGOCOCCAL POLYSACCHARIDE, SEROGROUPS A,C,Y,W-135, QUAD, SUBCU
90736	ZOSTER (SHINGLES) LIVE, SUBCU
90740	HEPB VACC, ILL PAT 3 DOSE IM
90750	ZOSTER (shingles) VACC, IM
90675	RABIES VACCINE, IM
90676	RABIES VACCINE, ID

Covered Travel Immunizations (All Ages)	
Procedure/Description	
90585	Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use
90690	Typhoid vaccine, live, oral
90691	Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use
90717	Yellow fever vaccine, live, for subcutaneous use
90738	Japanese encephalitis virus vaccine, inactivated, for intramuscular use

Coverage Limitations:

- Shingles Vaccines is limited to two (2) per lifetime.
- HPV is limited to three (3) per lifetime.
- Up to fifteen (15) administrations are reimbursable per day.

COVID

Reimbursement Requirements

This policy applies to U.S. Food and Drug Administration (FDA) approved and U.S. Centers for Disease Control (CDC) recommended COVID-19 vaccines and coverage of administration of those vaccines. This applies to vaccines meeting FDA guidelines. This includes vaccines approved through Emergency Use Authorization process. This policy applies to vaccines and administrations through the Rhode Island COVID-19 State of Emergency.

Vaccine codes will not be reimbursed at this time, as all vaccines will be provided at no cost to providers through the federal government. Neighborhood is requiring that providers continue to bill vaccine CPT codes for the purposes of data collection.



Vaccine administration codes will be covered and separately reimbursed according to the codes identified in this policy.

Please reference Children’s Care Payment Policy for information on COVID Vaccine Counseling.

The below table represents COVID vaccines and administration codes.

CPT Code	Description
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use. Pfizer-BioNTech COVID-19 Vaccine
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose Pfizer-BioNTech COVID-19 First Dose
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose Pfizer-BioNTech COVID-19 Second Dose
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose Pfizer-BioNTech COVID-19 Third Dose
0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; Booster Pfizer-BioNTech COVID-19 Booster
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use Moderna COVID-19 Vaccine
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease

	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose Moderna COVID-19 First Dose
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose Moderna COVID-19 Second Dose
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose Moderna COVID-19 Third Dose
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use Johnson & Johnson COVID-19 Vaccine
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, single dose Johnson & Johnson Administration
0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage; booster dose Johnson & Johnson Booster Dose
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use Novavax COVID-19 Vaccine
0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose Novavax COVID-19 First Dose

0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose Novavax COVID-19 Second Dose
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech COVID-19 Vaccine
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose Pfizer-BioNTech COVID-19 First Dose
0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose Pfizer-BioNTech COVID-19 Second Dose
0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose Pfizer-BioNTech COVID-19 Third Dose
0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose Pfizer-BioNTech COVID-19 Booster
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Vaccine
0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose

	Moderna COVID-19 Booster Dose
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech COVID-19 Pediatric Vaccine
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Pfizer-BioNTech COVID-19 First Dose
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Pfizer-BioNTech COVID-19 Second Dose
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose Pfizer-BioNTech COVID-19 Third Dose
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose Pfizer-BioNTech COVID-19 Booster Dose
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech Covid-19 Pediatric Vaccine
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3

	mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose Pfizer-BioNTech COVID-19 First Dose
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose Pfizer-BioNTech COVID-19 Second Dose
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose Pfizer-BioNTech COVID-19 Third Dose
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Moderna COVID-19 Vaccine
0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years Moderna COVID-19 First Dose
0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years Moderna COVID-19 Second Dose
0093A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years Moderna COVID-19 Third Dose
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease

	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over Moderna COVID-19 Booster Dose
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Pediatric Vaccine
0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose Moderna COVID-19 First Dose
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose Moderna COVID-19 Second Dose
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose Moderna COVID-19 Third Dose
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech COVID-19 Vaccine
0124A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose Pfizer-BioNTech COVID-19 Booster Dose
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Moderna COVID-19 Vaccine

0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose Moderna COVID-19 Booster Dose
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Moderna COVID-19 Vaccine
0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose Moderna COVID-19 Booster Dose
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Pfizer-BioNTech COVID-19 Vaccine
0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose Pfizer-BioNTech COVID-19 Booster Dose

Claim Submission

Billable services are subject to contractual agreements, when applicable. Providers are required to submit complete claims for payment within contractually determined timely filing guidelines.

Coding must meet standards defined by the American Medical Association's Current Procedural Terminology Editorial Panel's (CPT®) codebook, the International Statistical Classification of Diseases and Related Health Problems, 10th revision, Clinical Modification (ICD-10-CM), and the Healthcare Common Procedure Coding System (HCPCS) Level II.

Vaccine codes must be billed to NHPRI along with the appropriate administration codes for reimbursement. Administration codes submitted without the corresponding vaccine code will result in denial.

Documentation Requirements



Neighborhood reserves the right to request medical records for any service billed. Documentation in the medical record must support the service(s) billed as well as the medical necessity of the service(s). Neighborhood follows CMS standards for proper documentation requirements.

Member Responsibility

Commercial plans include cost sharing provisions for coinsurance, copays, and deductibles. Members may have out of pocket expenses based on individual plan selection and utilization. Please review cost sharing obligations or contact Member Services prior to finalizing member charges.

Coding

Non-COVID related administration coding (All Lines of Business)

Procedure/Description	
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered
90461	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
90472	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)
90474	Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)
G0008	Administration of influenza virus vaccine
G0009	Administration of pneumococcal vaccine
G0010	Administration of hepatitis B vaccine

Disclaimer

This payment policy is informational only and is not intended to address every situation related to reimbursement for healthcare services; therefore, it is not a guarantee of reimbursement.

Claim payments are subject to the following, which include but are not limited to: Neighborhood Health Plan of Rhode Island benefit coverage, member eligibility, claims payment edit rules, coding and documentation guidelines, authorization policies, provider contract agreements, and state and federal regulations. References to CPT or other sources are for definitional purposes only.



This policy may not be implemented exactly the same way on the different electronic claims processing systems used by Neighborhood due to programming or other constraints; however, Neighborhood strives to minimize these variations.

The information in this policy is accurate and current as of the date of publication; however, medical practices, technology, and knowledge are constantly changing. Neighborhood reserves the right to update this payment policy at any time. All services billed to Neighborhood for reimbursement are subject to audit.

Document History

Date	Action
03/29/2023	Removed PCP limitation from Medicaid and Commercial
01/01/2023	Policy Review Date. Updated COVID vaccine/administration table to include new codes. Removed language under INTEGRITY COVID section - no longer need to bill original Medicare, NHP reimburses.
11/12/2021	Combined COVID Vaccine Payment Policy with Immunization and Vaccine Payment Policy. Added pediatric COVID vaccine and admin codes, Moderna and Janssen booster codes. Updated COVID vaccine/administration requirements for Integrity members effective 1/1/22.
05/25/2021	Policy Review and Effective Date